CELEX: 62007TJ0493
Community trade mark
Invalidity proceedings
Community word mark FAMOXIN
Earlier national word marks LANOXIN
Relative ground for refusal
No likelihood of confusion
Article 8(1)(b) and Article 52(1)(a) of Regulation (EC) No 40/94 (now Article 8(1)(b) and Article 53(1)(a) of Regulation (EC) No 207/2009)
Proof of use
Article 56(2) and (3) of Regulation No 40/94 (now Article 57(2) and (3) of Regulation No 207/2009)

Three actions brought against the decisions of the First Board of Appeal of the Office for Harmonisation in the Internal Market
(Trade Marks and Designs) of 14 September 2007 (Case R 8/2007-1), 20 November 2007 (Case R 10/2007-1) and 19 November 2007
(Case R 9/2007-1), relating to cancellation proceedings between, on the one hand, GlaxoSmithkline SpA, Laboratórios Wellcome
De Portugal L
da
and The Wellcome Foundation Ltd, and, on the other, Serono Genetics Institute SA.
Information relating to the case
Registered Community trade mark subject of the application for a declaration of invalidity:
Community word mark FAMOXIN for goods and services in Class 5 – Application No 2491298
Proprietor of the Community trade mark:
Serono Genetics Institute SA
Party requesting the declaration of invalidity of the Community trade mark:
GlaxoSmithkline SpA ; Laboratórios Wellcome de Portugal, L
da
; and The Wellcome Foundation Ltd
Trade mark right of the party requesting the declaration of invalidity:
National word mark LANOXIN for goods in Class 5
Decision of the Cancellation Division:
Applications dismissed
Decision of the Board of Appeal:
Appeals dismissed
Operative part
The Court:
1.
Joins Cases T-493/07, T-26/08 and T-27/08 for the purposes of the present judgment;
2.
Dismisses the actions;
3.
Orders GlaxoSmithKline SpA, Laboratórios Wellcome de Portugal, Lda and The Wellcome Foundation Ltd to pay the costs.